SCHEMBL352117

SCHEMBL352117

CNC(=O)c1c(C)n[nH]c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.53
LMNA P02545 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP2C19 P33261 1/20 0.40
DYRK1A Q13627 1/20 0.39
BRD4 O60885 2/20 0.39
BRPF1 P55201 2/20 0.39
CREBBP Q92793 2/20 0.39
GAA P10253 1/20 0.37
AR P10275 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPK1 P28482 1/20 0.36
YTHDC1 Q96MU7 1/20 0.36
EP300 Q09472 1/20 0.35
CHEK1 O14757 1/20 0.35
RET P07949 1/20 0.35
PDGFRB P09619 1/20 0.35
PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15911113 0.77 PDE4D (0.51) PDE4DLMNAL3MBTL1CYP2C19DYRK1A
SCHEMBL30090296 0.76 PDE4D (0.50) PDE4DLMNAL3MBTL1CYP2C19KDM4E
SCHEMBL5700603 0.76 PDE4D (0.50) PDE4DLMNAL3MBTL1CYP2C19KDM4E
SCHEMBL1640767 0.76 PDE4D (0.59) PDE4DLMNAL3MBTL1CYP2C19DYRK1A
SCHEMBL1663754 0.76 PDE4D (0.59) PDE4DLMNAL3MBTL1CYP2C19DYRK1A
SCHEMBL23926008 0.74 PDE4D (0.57) PDE4DLMNAL3MBTL1CYP2C19DYRK1A
SCHEMBL15777023 0.74 PDE4D (0.57) PDE4DLMNAL3MBTL1CYP2C19DYRK1A
SCHEMBL4631791 0.73 AURKA (0.51) LMNAL3MBTL1GAAMEN1KMT2A
SCHEMBL9125632 0.73 CSNK2A2 (0.56) PDE4DLMNAL3MBTL1CYP2C19KDM4E
SCHEMBL24131083 0.72 TAS1R3 (0.53) LMNAL3MBTL1CYP2C19GAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4341247-A1 RIP1 MODULATORS INCLUDING AZETIDINE CYCLIC UREAS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2024-03-27 EP disclosed
CN-117355506-A RIP1 modulators comprising azetidine cyclic ureas, preparation and use thereof 维泰瑞隆有限公司 2024-01-05 CN disclosed
WO-2022242581-A1 RIP1 MODULATORS INCLUDING AZETIDINE CYCLIC UREAS, PREPARATIONS, AND USES THEREOF Sironax Ltd. (KY) 2022-11-24 WO disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA PDE4D 1640/4885LMNA 4293/4885L3MBTL1 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.